Home/Palvella Therapeutics/Jay T. Backstrom, MD, MPH
JT

Jay T. Backstrom, MD, MPH

Chief Medical Officer

Palvella Therapeutics

Palvella Therapeutics Pipeline

DrugIndicationPhase
QTORIN 3.9% Rapamycin Anhydrous GelPachyonychia Congenita (PC)Phase 3